MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock News

NYSEARCA:MTNB - NYSE Arca - US5768103039 - Common Stock - Currency: USD

0.96 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MTNB Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Benzinga - Mentions: NVAX PTIX RGC ABP ...

12 Health Care Stocks Moving In Monday's Intraday Session

2 months ago - By: Benzinga - Mentions: WORX XNCR VYGR AQB ...

12 Health Care Stocks Moving In Friday's After-Market Session

4 months ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

5 months ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

a year ago - By: InvestorPlace

MTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023

5 months ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

6 months ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Receives NYSE Noncompliance Notice

9 months ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

a year ago - By: InvestorPlace

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

a year ago - By: InvestorPlace - Mentions: LILM BKSY ASM HOOK ...

Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch

a year ago - By: Matinas BioPharma Holdings, Inc.

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

a year ago - By: InvestorPlace

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Prices $10 Million Registered Direct Offering

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

a year ago - By: Matinas BioPharma Holdings, Inc.

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

a year ago - By: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis